Sepracor has released the results of a randomized, double-blind, placebo-controlled, two-week study of its Lunesta brand of eszopiclone for treating older insomnia patients. The results showed an improvement in patients’ sleep maintenance, sleep induction, and sleep duration.
Patients administered the drug, known as LUNESTA 2 mg, also reported reduced time to sleep onset, reduced wake time after sleep onset, increase sleep efficiency and increased total sleep time. The most commonly reported negative effects were pain, dry mouth, dizziness, somnolence, and unpleasant taste.
The results were consistent with a previously published two week trial in SLEEP, a journal studying the administration of Lunesta to elderly patients.
